Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons

Molecular Psychiatry

Volumn 24, Issue 6, 2019, Pages 795-807

  Vadodaria, Krishna C ^a   Ji, Yuan ^b,c   Skime, Michelle ^d   Paquola, Apua ^a,e   Nelson, Timothy ^c   Hall Flavin, Daniel ^d   Fredlender, Callie ^a   Heard, Kelly J ^a   Deng, Yalin ^a   Le, Amy T ^a   Dave, Sonia ^a   Fung, Lianna ^a   Li, Xinyi ^a   Marchetto, Maria C ^a   Weinshilboum, Richard ^c   Gage, Fred H ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d MAYO CLINIC   (United States)

^e LIEBER INSTITUTE FOR BRAIN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERACTIVITY; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOLECULAR IMAGING; NERVE CELL; NEUROTRANSMISSION; PLURIPOTENT STEM CELL; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; AKATHISIA; COHORT ANALYSIS; DRUG EFFECT; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RESTLESSNESS; SYNAPTIC TRANSMISSION; TREATMENT RESISTANT DEPRESSION;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MIDDLE AGED; NEURONS; PSYCHOMOTOR AGITATION; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 85060917402     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/s41380-019-0363-y     Document Type: Article

References (37)

1. http://www.who.int/mediacentre/factsheets/fs369/en/, http://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml, https://www.nlm.nih.gov/medlineplus/ency/article/000945.htm & http://www.dbsalliance.org/site/PageServer?pagename=education_statistics_depression
2. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3:171–8.
3. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–38.
4. Charney DS, Buxbaum JD, Sklar P, Nestler EJ. Neurobiology of mental illness. Oxford University Press: 2013.
5. Breen G, et al. Translating genome-wide association findings into new therapeutics for psychiatry. Nat Neurosci. 2016;19:1392–6.
6. Levinson DF, et al. Genetic studies of major depressive disorder: why are there no genome-wide association study findings and what can we do about it? Biol Psychiatry. 2014;76:510–2.
7. Wray NR et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81. 10.1038/s41588-018-0090-3
8. Soliman MA, Aboharb F, Zeltner N, Studer L. Pluripotent stem cells in neuropsychiatric disorders. Mol Psychiatry. 2017;22:1241–9.
9. Brennand KJ, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221–5.
10. Robicsek O, et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry. 2013;18:1067–76.
11. Madison JM, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol Psychiatry. 2015;20:703–17.
12. Mertens J, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95–9.
13. Mrazek DA, et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol. 2014;34:313–7.
14. Drysdale AT, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.
15. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–9.
16. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10:1116–24.
17. McGrath CL, et al. Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry. 2014;76:527–35.
18. Mayberg HS, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–60.
19. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology. 2010;35:192–216.
20. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013;137:119–31.
21. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15:473–500.
22. Hrdina PD, Du L. Levels of serotonin receptor 2A higher in suicide victims? Am J Psychiatry. 2001;158:147–8.
23. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7:249–64.
24. Knight AR, et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiede Arch Pharmacol. 2004;370:114–23.
25. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;114:559–65.
26. Benekareddy M, Vadodaria KC, Nair AR, Vaidya VA. Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stress-induced immediate early gene responses, and specific transcriptional changes that arise following early life stress. Biol Psychiatry. 2011;70:1024–32.
27. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28:402–12.
28. Sarkisyan G, Roberts AJ, Hedlund PB. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res. 2010;209:99–108.
29. Mullins UL, Gianutsos G, Eison AS. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology. 1999;21:352–67.
30. Sowa-Kucma M, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep. 2017;69:595–601.
31. Vadodaria KC, Amatya DN, Marchetto MC, Gage FH. Modeling psychiatric disorders using patient stem cell-derived neurons: a way forward. Genome Med. 2018;10:1.
32. Rush AJ, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493–501.
33. Marchetto MC, et al. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol Psychiatry. 2017;22:820–35.
34. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
35. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.
36. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
37. Santos R, et al. Differentiation of inflammation-responsive astrocytes from glial progenitors generated from human induced pluripotent stem cells. Stem Cell Rep. 2017;8:1757–69.